文献速递腹部泌尿生殖MR

功能性肝脏影像评分预测肝细胞癌手术切除后预后的模型开发与验证:一项多中心研究

Predictive model development and validation of functional liver imaging score for prognosis of patients with hepatocellular carcinoma after surgical resection: a multicenter study.
PubMed 文献 · Radiol Med · 2025-11-02

本研究纳入694例经病理证实、接受肝特异性对比剂增强MRI及肝切除术的肝细胞癌患者,基于肝细胞期MRI特征构建功能性肝脏影像评分(FLIS),并将FLIS≤2、AFP>400 ng/mL、肿瘤>5 cm和主要肝切除作为总生存期不良的独立预测因子建立预后模型,该模型在训练队列、内部验证队列和外部验证队列的Harrell一致性指数分别为0.91、0.96和0.94,显著优于单用FLIS和传统临床模型。

要点

  • FLIS由肝细胞期肝脏强化、胆道排泄和门静脉信号强度三项特征各赋0–2分计算得出。
  • FLIS≤2、AFP>400 ng/mL、肿瘤>5 cm和主要肝切除是不良总生存期的独立预测因子。
  • FLIS联合临床变量的模型在训练、内部验证和外部验证队列的一致性指数分别为0.91、0.96和0.94。

核心结论

  • FLIS是一种简单、无创的影像生物标志物,用于评估肝功能和预测肝细胞癌患者结局;与关键临床变量整合后,FLIS模型对总生存期和无复发生存期表现出优异的区分度和校准度,可提供准确的术后预后分层,并在未来临床应用中显示出指导监测和改善长期生存结局的巨大潜力。

研究设计与样本

  • 多中心研究,共纳入694例经病理证实、接受肝特异性对比剂(钆塞酸二钠或钆贝葡胺)增强MRI及后续肝切除术的肝细胞癌患者,采用多变量Cox回归筛选独立预测因子并构建预后模型,在训练队列、内部验证队列和外部验证队列中验证。

关键影像表现/征象

  • FLIS通过肝细胞期MRI的三项特征计算:肝脏强化、胆道排泄和门静脉信号强度,每项赋0–2分。
  • FLIS≤2、甲胎蛋白>400 ng/mL、肿瘤大小>5 cm和主要肝切除被确定为总生存期较差的独立预测因子。

诊断标准与关键数值

  • FLIS≤2为总生存期较差的独立预测因子。
  • 甲胎蛋白>400 ng/mL为总生存期较差的独立预测因子。
  • 肿瘤大小>5 cm为总生存期较差的独立预测因子。
  • 主要肝切除为总生存期较差的独立预测因子。
  • 预测模型Harrell一致性指数:训练队列0.91,内部验证队列0.96,外部验证队列0.94。

临床应用与阅片要点

  • 基于肝细胞期MRI的FLIS可用于肝细胞癌切除术后患者的肝功能评估和预后分层。
  • FLIS联合甲胎蛋白、肿瘤大小和切除范围构建的模型有助于识别高危患者。
  • Kaplan-Meier分析显示低风险患者较高风险患者在所有队列中总生存期和无复发生存期均显著更好(p<0.05)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

PURPOSE: This study aimed to develop and validate a prognostic model for hepatocellular carcinoma (HCC) patients undergoing liver resection, using the functional liver imaging score (FLIS) derived from hepatobiliary-specific contrast-enhanced magnetic resonance imaging (MRI).

MATERIAL AND METHODS: A total of 694 pathologically confirmed HCC patients who underwent hepatobiliary-specific MRI with either gadoxetic acid or gadobenate dimeglumine and subsequent liver resection were included. FLIS was calculated by assigning 0-2 points to three hepatobiliary-phase MRI features: hepatic enhancement, biliary excretion, and portal vein signal intensity. Multivariable Cox regression identified AFP level, tumor size, and extent of resection as independent predictors of overall survival (OS).

RESULTS: FLIS ≤ 2, alpha-fetoprotein (AFP) > 400 ng/mL, tumor size > 5 cm, and major resection were identified as independent predictors of worse OS. A predictive model combining these factors demonstrated excellent prognostic performance, with Harrell's concordance indices of 0.91 in the training cohort and 0.96 internal validation cohort, and 0.94 in external validation cohort. The FLIS-based model significantly outperformed FLIS alone and conventional clinical models (p < 0.05). Kaplan-Meier survival analysis showed that low-risk patients had significantly better OS and recurrence-free survival (RFS) compared to high-risk patients across all cohorts (p < 0.05).

CONCLUSION: FLIS is a simple, non-invasive imaging biomarker for evaluating liver function and predicting outcomes in HCC patients. When integrated with key clinical variables, the FLIS-based model demonstrates excellent discrimination and calibration for OS and RFS, providing accurate postoperative prognostic stratification and showing great potential for guiding surveillance and improving long-term survival outcomes in future clinical applications.

来源:Radiol Med,查看原文。版权归原作者所有。

引用

  1. Ding F, Ota T, Cai S, et al. Predictive model development and validation of functional liver imaging score for prognosis of patients with hepatocellular carcinoma after surgical resection: a multicenter study. Radiol Med. 2025. PMID: 41176590. doi:10.1007/s11547-025-02110-y

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。